2018
DOI: 10.1159/000491986
|View full text |Cite
|
Sign up to set email alerts
|

Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume

Abstract: Background: Reductions in the volume of brain white matter are a common feature in schizophrenia and bipolar disorder while the association between white matter and polygenic schizophrenia-related risk is unclear. To look at the intermediate state between health and the full-blown disorder, we investigated this aspect in groups of patients before and after the onset of psychosis. Methods: On a 3 Tesla scanner, total and regional white matter volumes were investigated by structural magnetic resonance imaging (M… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
6
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 48 publications
1
6
0
Order By: Relevance
“…In particular, polygenic risk scores for schizophrenia may not be associated with measures of brain volume in healthy individuals or in those with psychotic disorders. This explanation is consistent with findings from previous research in populations of largely European ancestry ( Reus et al, 2017 ; Harrisberger et al, 2018 ; Lancaster et al, 2018 ; Simões et al, 2020 ). For example, no associations between PRS for schizophrenia and for bipolar disorder with either subcortical volume or WM microstructure, were found in the United Kingdom Biobank ( Reus et al, 2017 ).…”
Section: Discussionsupporting
confidence: 93%
“…In particular, polygenic risk scores for schizophrenia may not be associated with measures of brain volume in healthy individuals or in those with psychotic disorders. This explanation is consistent with findings from previous research in populations of largely European ancestry ( Reus et al, 2017 ; Harrisberger et al, 2018 ; Lancaster et al, 2018 ; Simões et al, 2020 ). For example, no associations between PRS for schizophrenia and for bipolar disorder with either subcortical volume or WM microstructure, were found in the United Kingdom Biobank ( Reus et al, 2017 ).…”
Section: Discussionsupporting
confidence: 93%
“…The main limitations of this study were that the meta-analyses had heterogeneous quality (eResults in the Supplement) and that the literature search approach may have favored the selection of more commonly and readily studied domains that are more likely to be included in a meta-analysis. We cannot exclude the possibility that some promising advancements in the CHR-P field, despite having sufficient data, do not (yet) have a corresponding eligible meta-analysis, such as polygenic risk scores . However, in the current era, this possibility is becoming increasingly less likely, with meta-analyses being performed frequently, to the point that multiple meta-analyses are available for the same topic .…”
Section: Discussionmentioning
confidence: 97%
“…We cannot exclude the possibility that some promising advancements in the CHR-P field, despite having sufficient data, do not (yet) have a corresponding eligible metaanalysis, such as polygenic risk scores. 96 However, in the current era, this possibility is becoming increasingly less likely, with metaanalyses being performed frequently, to the point that multiple metaanalyses are available for the same topic. [97][98][99] In any case, for most putative domains that are difficult to study (or uncommonly studied), the current grade of evidence is unlikely to be remarkable, given the limited data.…”
Section: Limitationsmentioning
confidence: 99%
“…Although not yet clinically useful [199,200], PRS is one of the most commonly explored multivariate genetic markers and has shown some potential in the context of prodromal research to predict transition from high risk to psychosis [201,202]. This may enable stratifying individuals into groups of high and low risk of transition and delivery of treatment accordingly [203].…”
Section: B Biomarker and Predictionmentioning
confidence: 99%